Everyone Is Talking About GLP-1. Here's What You Actually Need to Know.
Semaglutide. Tirzepatide. Ozempic. Wegovy. Mounjaro. These names are everywhere — in medical journals, in Bollywood circles, in WhatsApp health groups. India's anti-obesity market grew 115% in 2025 on the back of GLP-1 drug launches. But the buzz has created as much confusion as clarity. Let's cut through it.
Who Are the Right Candidates?
What to Expect When You Start
GLP-1 isn't a pill you take and forget. Here's the honest picture:
Food "noise" — the constant mental chatter about what to eat next — quiets down meaningfully for most users.
Nausea, mild bloating common in weeks 1–4. Starting at low dose and titrating slowly (MetaFit's protocol) minimizes these significantly.
0.5–1 kg per week typical early on. Clinical trials show 13–20% total body weight reduction over 12–18 months with lifestyle changes.
GLP-1 suppresses appetite. It doesn't teach healthy habits or fix sleep and stress. Combine it with MetaFit's coaching for optimal, lasting results.
The MetaFit Assessment Process
🔬 What Your MetaFit Evaluation Includes
A New Era of Weight Loss Medicine
For decades, the only effective medical options for obesity were bariatric surgery — invasive, expensive, and inaccessible to most Indians. GLP-1 medications represent the first time in medical history that a weekly injection can produce surgical-level weight loss outcomes safely and reversibly. This is genuinely historic. If you've been struggling with weight despite doing "everything right," this era was made for you.
The people who struggle most with weight are often those working hardest against the toughest biology. They deserve the best tools medicine has to offer.
Explore the topic
- GLP-1 weight loss in India
The complete guide to GLP-1 therapy, results and safety for Indian patients.
- Check your GLP-1 eligibility
Find out whether doctor-supervised GLP-1 therapy is clinically appropriate for you.
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021 (STEP 1) — mean 14.9% body-weight reduction at 68 weeks.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022 (SURMOUNT-1) — up to 20.9% body-weight reduction at 72 weeks.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022 — roughly two-thirds of lost weight regained one year after stopping.
This article is for general information and is not a substitute for individual medical advice. Prescription medicines referenced here are regulated in India by the Central Drugs Standard Control Organisation (CDSCO) and are dispensed only against a valid prescription from a registered medical practitioner.
Ready to Start Your Weight Loss Journey?
Get a personalized medical assessment from MetaFit's expert doctors — tailored for the Indian lifestyle.
Book a Free ConsultationOr download the app to get started
